Affinity Asset Advisors’s Trevi Therapeutics TRVI Stock Holding History

Affinity Asset Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.6M	Sell	1,800,172 -200,000	-10%	-$2.91M	1.52%	20
2026 Q1	$23.9M	Sell	2,000,172 -150,000	-7%	-$1.68M	1.23%	26
2025 Q4	$26.9M	Sell	2,150,172 -649,828	-23%	-$7.51M	1.53%	21
2025 Q3	$25.6M	Buy	2,800,000 +265,942	+10%	+$1.99M	2.23%	17
2025 Q2	$13.9M	Buy	2,534,058 +1,284,058	+103%	+$7.99M	1.89%	16
2025 Q1	$7.86M	Buy	+1,250,000	New	+$5.96M	0.75%	31

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Affinity Asset Advisors's TRVI Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Trevi Therapeutics (TRVI) stake by 10% in Q2 2026, selling an estimated $2.91M and leaving 1,800,172 shares worth $33.6M. The position accounts for 1.52% of the portfolio, ranked #20.

Affinity Asset Advisors first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Affinity Asset Advisors held 1,800,172 shares of Trevi Therapeutics worth $33.6M as of Q2 2026.
Affinity Asset Advisors sold 200,000 Trevi Therapeutics shares in Q2 2026, an estimated $2.91M.
Trevi Therapeutics made up 1.52% of Affinity Asset Advisors's portfolio in Q2 2026, its #20 holding.
Affinity Asset Advisors first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.